Justin introduces Pluri (NASDAQ:PLUR)

Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine, food-tech and agtech and aims to establish partnerships that leverage the Company’s 3D cell-based technology to additional industries that require effective, mass cell production. Pluri also offers CDMO services. To learn more, visit us at [ Ссылка ]

CEO Updates on Recent Achievements & 2024 Goals ➡️ [ Ссылка ]
Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing ➡️ [ Ссылка ]
Pluri™ Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation ➡️ [ Ссылка ]

Trade With Justin ➡️ [ Ссылка ]
Business Inquiry ➡️ partner@blazecapital.com

This video is not investment advice. Disclaimer: [ Ссылка ]

Sponsored Content: Blaze Capital was paid $2,500 CAD for a marketing package, including this video. Blaze Capital does own a position in Pluri Inc. (NASDAQ:PLUR). Blaze Capital purchased shares in the open market - in the week before this video was published - which may have impacted the share price.

This YouTube video was conducted on behalf of Pluri Inc. (NASDAQ:PLUR) and was funded by Outside The Box Capital Inc. and/or affiliates after Blaze Capital was engaged by Outside The Box Capital Inc. to advertise for Pluri Inc. (NASDAQ:PLUR).

For our full disclaimer, please visit:
[ Ссылка ]

свернуть